GNLX
GENELUX CorpCompany Information
- Company Name
- GENELUX Corp
- CIK
- CIK0001231457
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- GNLX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- GNLX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-29
- Last sale
- 2026-08-31
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 117,456
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 9,799,064
- Shares outstanding
- 44,959,426
- Ownership
- 21.80%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -7.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 9 | 5 | - | 7 | 16 | 9 | 6 | 8 | 4 | 9 | 30 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | 9 | - | 5 | - | - | - | - | - | - | - | - | ||||||
| Marketable Securities | 9 | 17 | 9 | - | - | - | 22 | - | - | - | - | - | ||||||
| Short Term Investments | - | 17 | - | 16 | 21 | 19 | 22 | 28 | 26 | 16 | 14 | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | ||||||
| Assets Current | 19 | 27 | 15 | 22 | 29 | 36 | 32 | 36 | 35 | 21 | 24 | 31 | ||||||
| Property Plant And Equipment Net | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Long Term Investments | - | - | - | - | - | - | - | 1 | 7 | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Noncurrent | - | - | - | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 3 | ||||||
| Assets | 26 | 32 | 19 | 25 | 32 | 39 | 35 | 40 | 45 | 25 | 28 | 34 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 7 | 6 | 4 | 4 | 6 | 7 | 6 | 4 | 5 | 5 | 4 | 4 | ||||||
| Accrued Payroll Taxes Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 8 | 7 | 6 | 5 | 7 | 8 | 7 | 6 | 6 | 8 | 7 | 9 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Liabilities | 10 | 9 | 7 | 6 | 8 | 9 | 8 | 7 | 8 | 10 | 8 | 10 | ||||||
Stockholders Equity | ||||||||||||||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Additional Paid In Capital | 318 | 316 | 295 | 293 | 291 | 289 | 278 | 276 | 274 | 245 | 241 | 239 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -302 | -292 | -284 | -274 | -266 | -259 | -251 | -242 | -236 | -229 | -222 | -215 | ||||||
| Stockholders Equity | 16 | 23 | 12 | 19 | 24 | 30 | 26 | 33 | 38 | 15 | 19 | 24 | ||||||
| Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 2 | 1 | ||||||
| Liabilities And Stockholders Equity | 26 | 32 | 19 | 25 | 32 | 39 | 35 | 40 | 45 | 25 | 28 | 34 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Common Stock Shares Issued | 45 | 45 | 38 | - | 38 | 38 | 35 | 35 | 35 | 27 | 27 | 27 | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | 0 | 0 | 0 | 0 | - | 0 | - | ||||||
| Shares Outstanding | 45 | 45 | 38 | 38 | 38 | 38 | 35 | 35 | 35 | 27 | 27 | 27 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialGENELUX Corp (GNLX) — SEC Financial Statements & Analysis
GENELUX Corp (GNLX) is a pharmaceutical preparations company, incorporated in DE. GENELUX Corp trades on Nasdaq as: GNLX. GENELUX Corp (GNLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, GENELUX Corp carries a market cap of $135.33M, a P/E ratio of -3.80x, a P/B ratio of 8.40x, a P/S ratio of 9277.96x, an enterprise value of $126.14M, and an EV/EBITDA multiple of -3.48x. On profitability, it posts an operating margin of -396200.00%, a net margin of -373362.50%, a Return on Equity (ROE) of -177.93%, a Return on Assets (ROA) of -121.80%, and a Return on Invested Capital (ROIC) of -300.00%. Per share, it reports EPS of $-0.79, diluted EPS of $-0.79, free cash flow per share of $-0.64, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 17.13% year-over-year, and EPS growth of -1.14% year-over-year. On the balance sheet, it maintains a current ratio of 2.39x, a quick ratio of 2.33x, working capital of $11.15M, a debt-to-equity ratio of 0.63x, a debt ratio of 0.39, an interest coverage ratio of -4824.83x, free cash flow of $-28.68M (TTM), and net debt of $-9.18M. Figures sourced from SEC EDGAR.
- Market Cap
- $135.33M
- P/E TTM
- -3.80x
- EPS TTM
- $-0.79
- P/B TTM
- 8.40x
- ROE TTM
- -177.93%
- ROA TTM
- -121.80%
- Debt To Equity
- 0.63x
- Free Cash Flow TTM
- $-28.68M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is GENELUX Corp in?
GENELUX Corp (GNLX) operates in the Pharmaceutical Preparations industry.
What exchange does GNLX trade on?
GENELUX Corp (GNLX) trades on the Nasdaq.
Where is GENELUX Corp incorporated?
GENELUX Corp is incorporated in DE.
When was GENELUX Corp (GNLX)'s most recent SEC filing?
GENELUX Corp (GNLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is GNLX's market cap?
GENELUX Corp (GNLX) has a market capitalization of $135.33M as of 2026-06-30.
What is GNLX's EPS (earnings per share)?
GENELUX Corp (GNLX)'s trailing twelve month EPS is $-0.79 as of 2026-06-30.
What is GNLX's ROE (return on equity)?
GENELUX Corp (GNLX)'s trailing twelve month Return on Equity (ROE) is -177.93% as of 2026-06-30.
What is GNLX's ROA (return on assets)?
GENELUX Corp (GNLX)'s trailing twelve month Return on Assets (ROA) is -121.80% as of 2026-06-30.
What is GNLX's ROIC (return on invested capital)?
GENELUX Corp (GNLX)'s trailing twelve month Return on Invested Capital (ROIC) is -300.00% as of 2026-06-30.
What is GNLX's EV/EBITDA?
GENELUX Corp (GNLX)'s trailing twelve month EV/EBITDA is -3.48x as of 2026-06-30.